Scott Bizily - Apr 1, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal Officer
Signature
By: /s/ Scott Bizily
Stock symbol
FDMT
Transactions as of
Apr 1, 2024
Transactions value $
-$156,878
Form type
4
Date filed
4/3/2024, 07:18 PM
Previous filing
Mar 29, 2024
Next filing
Apr 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $8.64K +1.33K +76.68% $6.49* 3.07K Apr 1, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $23.4K +2.92K +95.01% $8.04* 5.99K Apr 1, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $31.5K +2K +33.35% $15.78 7.98K Apr 1, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $38.6K +1.91K +23.92% $20.24 9.89K Apr 1, 2024 Direct F1
transaction FDMT Common Stock Sale -$259K -8.15K -82.44% $31.78 1.74K Apr 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -1.33K -8.3% $0.00 14.7K Apr 1, 2024 Common Stock 1.33K $6.49 Direct F1, F2
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -2.92K -6.73% $0.00 40.4K Apr 1, 2024 Common Stock 2.92K $8.04 Direct F1, F3
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -2K -8.68% $0.00 21K Apr 1, 2024 Common Stock 2K $15.78 Direct F1, F4
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -1.91K -3.97% $0.00 46.2K Apr 1, 2024 Common Stock 1.91K $20.24 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F4 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F5 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.